Fiche du document
22 juin 2022
- doi: 10.53738/REVMED.2022.18.787.1269
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.787.1269
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35735152
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F53B564339C31
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Therapy Bronchial asthmaCiter ce document
J.D. Leuppi et al., « Nouveautés dans la prise en charge de l’asthme [Novelties in the Treatment of Asthma] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.787.1269
Métriques
Partage / Export
Résumé
For general practitioners there have been important novelties in the treatment of asthma due to recent modifications of the international guidelines from Global Initiative for Asthma (GINA). In Step 1, use of short-acting beta2-agonists (SABA) without concomitant inhaled corticosteroids (ICS) as controller is no longer recommended for lack of efficacy and safety reasons. Instead, low dose ICS-formoterol as needed is recommended. In Step 5, in patients with severe uncontrolled asthma GINA recommends targeted biologic therapies like interleukin antibodies. Asthma patients presenting simultaneously with symptoms of chronic obstructive pulmonary disease (COPD) should receive treatment containing ICS. Independent of the current corona pandemic, GINA recommendations stay in place.